BeiGene, Ltd.
https://www.beigene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BeiGene, Ltd.
October Outlook For US FDA Approvals: Goal Dates Are Sparse, But Backlog Looms
Upcoming user fee goal dates include AstraZeneca’s tremelimumab, Amicus’ AT-GAA, and drug delivery technology-driven NDAs from Supernus/US Worldmeds and scPharmaceuticals
China Closes In On Top 10 In Global Innovation Ranking
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.
Cage Fighting: Novel Drugs From MNCs, Chinese Rivals Compete In China Reimbursement Sector
After slashing the prices of their blockbuster drugs to gain wider patient access through China's main reimbursement program, multinationals are now beginning to face increasing challenges from local competitors.
Chinese-Language Podcast: ESMO上的中国数据
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- MapKure, LLC